Evidence map›Paper›PMID 41667841›Full record

ArticleNPJ digital medicine2026

Telemonitoring modalities in heart failure: comparative effectiveness across the heart failure population-a meta-analysis.

Niels T B Scholte, Pascal R D Clephas, Eric Boersma, Muhammed T Gürgöze, Eelko Ronner, Lida Feyz, Rudolf A de Boer, Robert M A van der Boon, Jasper J Brugts

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Niels T B Scholte *Department of Cardiology, Thorax Centre, Cardiovascular Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Pascal R D Clephas *Department of Cardiology, Thorax Centre, Cardiovascular Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Eric BoersmaDepartment of Cardiology, Thorax Centre, Cardiovascular Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Muhammed T GürgözeDepartment of Cardiology, Thorax Centre, Cardiovascular Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Eelko RonnerDepartment of Cardiology, Reinier de Graaf Hospital, Delft, The Netherlands.
Lida FeyzDepartment of Cardiology, Thorax Centre, Cardiovascular Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Rudolf A de BoerDepartment of Cardiology, Thorax Centre, Cardiovascular Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Robert M A van der Boon *Department of Cardiology, Thorax Centre, Cardiovascular Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Jasper J Brugts *Department of Cardiology, Reinier de Graaf Hospital, Delft, The Netherlands. j.brugts@erasmusmc.nl.

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek 628.011.214
6 · The paper itself

Abstract

Remote monitoring (RM) is effective for managing heart failure (HF), but it remains unclear which patients benefit most from which RM modality. We conducted a meta-analysis of 79 randomised trials including 31,669 patients comparing RM with standard care for total and first HF hospitalisations and all-cause mortality. Subgroup analyses evaluated effects by geographic region and HF status, and meta-regression assessed the influence of age, left ventricular ejection fraction, New York Heart Association class, sex, and publication year. Network meta-analysis ranked RM modalities using Surface Under the Cumulative Ranking scores. Overall, RM reduced total HF hospitalisations (incidence rate ratio 0.81, 95% confidence interval [CI] 0.72-0.91), first HF hospitalisations (risk ratio 0.82, 95% CI: 0.76-0.88), and all-cause mortality (risk ratio 0.90, 95% CI: 0.84-0.95). Subgroup and meta-regression analyses showed consistent benefits across patient and study characteristics without significant interaction effects. In network meta-analysis, invasive hemodynamic monitoring ranked highest for reducing total HF hospitalisations, while structured telephone support ranked highest for reducing first HF hospitalisation and all-cause mortality. RM consistently improves HF outcomes across a range of patient and study characteristics, supporting its broad use. However, based on these characteristics, current evidence does not allow targeted RM implementation for specific patients most likely to benefit.

Identifiers

PMID41667841
PMCPMC13002972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.